Correlation Between Cns Pharmaceuticals and NeuBase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cns Pharmaceuticals and NeuBase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cns Pharmaceuticals and NeuBase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cns Pharmaceuticals and NeuBase Therapeutics, you can compare the effects of market volatilities on Cns Pharmaceuticals and NeuBase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cns Pharmaceuticals with a short position of NeuBase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cns Pharmaceuticals and NeuBase Therapeutics.

Diversification Opportunities for Cns Pharmaceuticals and NeuBase Therapeutics

0.65

Correlation Coefficient

Cns Pharmaceuticals  NeuBase Therapeutics

Poor diversification

The 3 months correlation between Cns and NeuBase is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Cns Pharmaceuticals and NeuBase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NeuBase Therapeutics and Cns Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cns Pharmaceuticals are associated (or correlated) with NeuBase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NeuBase Therapeutics has no effect on the direction of Cns Pharmaceuticals i.e., Cns Pharmaceuticals and NeuBase Therapeutics go up and down completely randomly.

Pair Corralation between Cns Pharmaceuticals and NeuBase Therapeutics

Given the investment horizon of 90 days Cns Pharmaceuticals is expected to generate 2.82 times more return on investment than NeuBase Therapeutics. However, Cns Pharmaceuticals is 2.82 times more volatile than NeuBase Therapeutics. It trades about 0.03 of its potential returns per unit of risk. NeuBase Therapeutics is currently generating about -0.38 per unit of risk. If you would invest  22.00  in Cns Pharmaceuticals on March 4, 2024 and sell it today you would earn a total of  0.00  from holding Cns Pharmaceuticals or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	42.86%
Values	Daily Returns

Cns Pharmaceuticals  vs.  NeuBase Therapeutics

Cns Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in July 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

NeuBase Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days NeuBase Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in July 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Cns Pharmaceuticals and NeuBase Therapeutics

The main advantage of trading using opposite Cns Pharmaceuticals and NeuBase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cns Pharmaceuticals position performs unexpectedly, NeuBase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuBase Therapeutics will offset losses from the drop in NeuBase Therapeutics' long position.

The idea behind Cns Pharmaceuticals and NeuBase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.